Introduction: Transradial cardiac catheterization has achieved significant favor in recent years; however, it might lead to a significant complication of radial artery occlusion (RAO). The medical approach to this phenomenon is a matter of debate; particularly by the emergence of novel oral anticoagulants; however, data on these agents for RAO treatment is considerably limited which is aimed to be assessed in this study using apixaban.
Methods: The current pilot double-blinded randomized clinical-trial was conducted on 30 patients with RAO following transradial coronary angiography who were randomly assigned to treatment with apixaban (2.5 mg twice daily) versus coservative approach for a period of 30 days. A Doppler ultrasonography was performed at baseline and by the end of the interventions assessing radial artery diameter and the arterial patency resolution. Demographic, medical, medication and clinical characteristics were gathered.
Results: Regardless of the medications, radial artery resolution was occurred in 21 (70%) of the patients with no association with age (P-value=0.62), gender (P-value=0.74), body mass index (P-value=0.23), smoking (P-value=0.64), diabetes (P-value=0.999), hypertension (P-value=0.74), statins (P-value=0.999), antiplatelet therapy (P-value=0.999), length of angiography (P-value=0.216) and follow-up arterial diameter (P-value=0.304). Recanalization occurred in 13 (86.7%) cases of treatment with apixaban versus 8 (53.3%) individuals of the control group representing a significant difference (P-value=0.046).
Conclusion: Based on the findings of this study, none of the Demographic, medical, medication and clinical factors were associated with arterial recanalization. Nevertheless, one-month use of apixaban in 2.5 mg twice-daily dose could appropriately lead to radial artery patency resolution.